查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403339

到 2030 年有毒药物筛检市场预测：按类型、测试类型、技术、最终用户和地区分類的全球分析

Toxicology Drug Screening Market Forecasts to 2030 - Global Analysis By Type, Test Type, Technology, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球有毒药物筛检市场规模为 133.4 亿美元，预计预测期内复合年增长率为 10.77%，到 2030 年将达到 273 亿美元。

医学诊断的重要组成部分之一是有毒药物筛检，即检查血液、尿液和头髮等生物样本中的药物及其代谢物。此步骤在许多情况下都是必不可少的，包括职场检查、法医学调查和临床评估。此外，有毒药物筛检可以透过使用层析法-质谱法和免疫分析等先进的分析技术来检测各种物质，包括毒素、非法药物和免疫测量药。

根据IFPMA 2021年报告，生物製药产业的年度研发支出是航太和国防工业的7.3倍，是化学工业的6.5倍，是软体和电脑服务产业的1.5倍。

药物滥用增加

推动有毒药物筛检市场的主要因素之一是药物滥用发生率的上升，包括传统药物和新开发的合成物质。此外，比以往任何时候都更需要有效的筛检方法来识别和治疗药物滥用，特别是考虑到鸦片类药物危机。为了应对这一驱动因素，市场开发了能够检测多种物质的新型筛检技术，包括对现有筛选技术构成挑战的新合成药物。

新物质鑑定困难

一个主要障碍是设计药物和新型精神活性物质 (NPS) 的快速崛起，这使得传统的毒性筛检技术不断复杂化。随着药物滥用领域的变化，筛检分析很难跟上非法药物配方的动态变化。此外，为了因应新化合物的检测，需要透过不断的研发来提升筛检能力。

尖端筛检技术的开发

开发更先进、更全面的筛检技术潜力巨大。质谱和层析法等分析技术的持续研究和创新正在提高灵敏度和特异性，从而能够检测更广泛的物质。此外，投资尖端技术将使相关人员能够更准确、更有效地满足不断变化的毒理学筛检需求。

设计药物的快速发展

设计药物和新型精神活性物质（NPS）的开发对现有的毒理学筛检技术构成了严重威胁。这些物质正在迅速发展，使得利用筛检分析来识别和检测新化合物变得困难。此外，这可能导致假阴性结果并降低药物测试的有效性。

COVID-19 的影响：

COVID-19 大流行对有毒药物筛检市场产生了重大影响，并改变了医疗保健优先事项和程序。由于重点解决突发公共卫生事件，药物检测项目和其他常规医疗保健服务已暂停。毒理学测试，特别是对重要工作人员和急诊室的毒理学测试，仍然是必要的，但大流行给样本收集、实验室操作和一般物流带来了挑战。此外，投资尖端毒理学技术的决定也受到大流行期间预算限制和经济不确定性的影响。

预测期内心血管疾病药物筛检领域可望成为最大

心血管疾病药物筛检领域预计将占最大份额。全世界发病和死亡的主要原因是心血管疾病，包括血脂异常症和高血压等疾病。因此，药物研发最重要的方面之一就是针对心血管疾病的药物筛检。此外，确定针对心臟和血管健康风险因素（如血压、胆固醇和凝血因子）的药物和治疗方法是心血管药物筛检市场的核心。

诊断实验室产业预计在预测期内复合年增长率最高。

诊断实验室领域预计在预测期内复合年增长率最高。诊断实验室提供各种用于疾病诊断和监测的测试，使其成为医疗保健过程的重要组成部分。此外，慢性病盛行率的上升和诊断技术的进步增加了对先进检测服务的需求。由于诊断实验室在精准和个人化医疗中的关键作用以及与製药公司和医疗保健提供者的合作伙伴关係，诊断实验室在该市场的持续成长中处于有利地位。

占比最大的地区：

预计北美将占据最大份额。促成这一优势的因素有很多，包括对研发的大量投资、完善的诊断实验室网路、慢性病的高盛行率以及先进的医疗基础设施。尤其美国，由于其强大的医疗保健系统和诊断技术的不断进步，成为推动市场成长的主要因素。此外，北美继续主导诊断实验室市场，部分原因是其强调个体化医疗保健和精准医疗。

复合年增长率最高的地区：

由于对先进诊断服务的需求不断增长、医疗保健意识不断提高以及感染疾病和慢性病的流行等因素，诊断测试市场预计将以亚太地区 (APAC) 最高的复合年增长率增长。随着诊断技术的显着进步，中国、印度和日本等国家正大力投资医疗基础设施。此外，该地区诊断实验室市场的强劲成长也归功于亚太国家对预防医学的重视和精准医学的采用。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球有毒药物筛检市场：依类型

  • 心血管疾病药物筛检
  • 减肥药筛检
  • 糖尿病药物筛检
  • 其他类型

第六章全球有毒药物筛检市场：依测试类型

  • 急性全身毒性
  • 经皮毒性
  • 致癌性的
  • 眼毒性
  • 遗传毒性
  • 神经毒性
  • 器官特异性毒性
  • 其他测试类型

第七章全球有毒药物筛检市场：依技术分类

  • 高通量筛检
  • 基因组学
  • 转录组学
  • 毒理基因组学
  • 分子筛检
  • 其他技术

第八章全球有毒药物筛检市场：依最终用户分类

  • 医院与创伤中心
  • 法医学研究所
  • 诊断实验室
  • 復健中心
  • 製药和生物技术公司
  • 其他最终用户

第九章全球有毒药物筛检市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Covance, Inc.
  • Agilent Technologies Inc.
  • Enzo Life Sciences Inc.
  • Danaher
  • Alere, Inc.
  • BioReliance, Inc.
  • Eurofins Scientific
  • Bio-Rad Laboratories Inc.
  • Promega Corporation
  • GE Healthcare
  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories International Inc.
Product Code: SMRC24564

According to Stratistics MRC, the Global Toxicology Drug Screening Market is accounted for $13.34 billion in 2023 and is expected to reach $27.30 billion by 2030 growing at a CAGR of 10.77% during the forecast period. One essential part of medical diagnostics is toxicology drug screening, which looks for drugs or their metabolites in biological samples like blood, urine, or hair. In a number of contexts, such as workplace testing, forensic investigations, and clinical evaluations, this procedure is essential. Moreover, toxicology drug screening can detect a variety of substances, including toxins, illicit drugs, and prescription medications, by using advanced analytical techniques like chromatography-mass spectrometry and immunoassays.

According to the IFPMA's 2021 report, the annual R&D spending by the biopharmaceutical industry is 7.3 times higher than that of the aerospace and defense industries, 6.5 times more than the chemicals industry, and 1.5 times more than the software and computer services industry.

Market Dynamics:

Driver:

Growing number of cases of substance abuse

One of the main factors propelling the toxicology drug screening market is the rising incidence of substance abuse, which includes both conventional drugs and newly developed synthetic substances. Additionally, particularly in light of the opioid crisis, there is a greater need than ever for efficient screening methods that identifies and treats drug abuse. In response to this driver, the market has developed novel testing methodologies that can detect a wide range of substances, including new designer drugs that present challenges to established screening techniques.

Restraint:

Difficulties in identifying novel substances

The quick rise of designer drugs and new psychoactive substances (NPS), which continuously complicate conventional toxicology screening techniques, is one major barrier. As the world of substance abuse changes, screening assays find it challenging to keep up with the dynamic nature of illicit drug formulations. Furthermore, enhancing screening capabilities through ongoing research and development is necessary to adjust to the detection of novel compounds.

Opportunity:

Development of cutting-edge screening technologies

The development of more sophisticated and all-encompassing screening technologies has a great deal of potential. Improved sensitivity, specificity, and the capacity to detect a wider variety of substances can result from ongoing research and innovation in analytical techniques like mass spectrometry and chromatography. Moreover, putting money into state-of-the-art technologies puts stakeholders in a position to more accurately and efficiently handle the changing demands of toxicology screening.

Threat:

Designer drugs quick evolution

The development of designer drugs and novel psychoactive substances (NPS) presents a serious threat to established toxicology screening techniques. These substances are evolving quickly, which makes it difficult for screening assays to identify and detect new compounds. Additionally, this could result in false negative results and reduce the effectiveness of drug testing.

COVID-19 Impact:

The COVID-19 pandemic has had a profound effect on the market for toxicology drug screening, changing healthcare priorities and procedures. Drug testing programs and other regular healthcare services have been disrupted as a result of the focus on solving the public health emergency. Although there was still a need for toxicology screening, especially for critical workers and in emergency rooms, the pandemic created difficulties for sample collection, laboratory operations, and general logistics. Furthermore, decisions to invest in cutting-edge toxicology technologies were influenced by budgetary constraints and economic uncertainties during the pandemic.

The Cardiovascular Disease Drug Screening segment is expected to be the largest during the forecast period

The cardiovascular disease drug screening segment is projected to hold the largest share. The world's leading causes of morbidity and mortality are cardiovascular diseases, which include ailments like dyslipidemia and hypertension. Thus, one of the most important aspects of pharmaceutical research and development is drug screening for cardiovascular diseases. Moreover, the identification of drugs and treatments that target heart and vascular health risk factors, such as blood pressure, cholesterol, and clotting factors, is central to the cardiovascular drug screening market.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

Over the course of the forecast period, the diagnostic laboratories segment is expected to have the highest CAGR. Diagnostic laboratories offer a wide variety of tests for the diagnosis and monitoring of diseases, which makes them essential to the healthcare process. Additionally, the need for advanced testing services has increased due to the rising prevalence of chronic conditions and the development of diagnostic technologies. Due to their crucial role in precision and personalized medicine, as well as their partnerships with pharmaceutical companies and healthcare providers, diagnostic laboratories are well-positioned for continued growth in this market.

Region with largest share:

North America is expected to hold the largest share. Many factors contribute to this prominence, including substantial investments in research and development, a well-established network of diagnostic laboratories, a high prevalence of chronic diseases, and an advanced healthcare infrastructure. The United States, in particular, is a major factor driving market growth because of its strong healthcare system and ongoing advancements in diagnostic technology. Furthermore, North America continues to dominate the market for diagnostic laboratories, in part because of the region's emphasis on personalized healthcare and precision medicine.

Region with highest CAGR:

The diagnostic laboratories market is expected to grow at the highest CAGR in the Asia-Pacific (APAC) region, due to factors such as growing demand for advanced diagnostic services, rising healthcare awareness, and the prevalence of infectious and chronic diseases. Alongside significant advancements in diagnostic technologies, nations like China, India, and Japan are investing heavily in their healthcare infrastructure. Moreover, the region's strong growth in the diagnostic laboratory market is also attributed to the emphasis on preventive healthcare and the adoption of precision medicine practices in several APAC countries.

Key players in the market:

Some of the key players in Toxicology Drug Screening market include Covance, Inc., Agilent Technologies Inc., Enzo Life Sciences Inc., Danaher, Alere, Inc., BioReliance, Inc., Eurofins Scientific, Bio-Rad Laboratories Inc., Promega Corporation, GE Healthcare, Thermo Fisher Scientific Inc and Charles River Laboratories International Inc.

Key Developments:

In November 2023, Danaher will acquire all of the outstanding shares of Abcam for $24 per share in cash, for a total enterprise value of approximately $5.7bn including assumed indebtedness and net of acquired cash.

In September 2023, Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.

In July 2023, Bio-Rad Laboratories, Inc. and QIAGEN N.V., today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

Types Covered:

  • Cardiovascular Disease Drug Screening
  • Obesity Drug Screening
  • Diabetes Drug Screening
  • Other Types

Test Types Covered:

  • Acute Systemic Toxicity
  • Dermal Toxicity
  • Carcinogenicity
  • Ocular Toxicity
  • Genotoxicity
  • Neurotoxicity
  • Organ-Specific Toxicity
  • Other Test Types

Technologies Covered:

  • High-Throughput Screening
  • Genomics
  • Transcriptomics
  • Toxicogenomics
  • Molecular Screening
  • Other Technologies

End Users Covered:

  • Hospitals and Trauma Centers
  • Forensic Laboratories
  • Diagnostic Laboratories
  • Rehabilitation Centers
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Toxicology Drug Screening Market, By Type

  • 5.1 Introduction
  • 5.2 Cardiovascular Disease Drug Screening
  • 5.3 Obesity Drug Screening
  • 5.4 Diabetes Drug Screening
  • 5.5 Other Types

6 Global Toxicology Drug Screening Market, By Test Type

  • 6.1 Introduction
  • 6.2 Acute Systemic Toxicity
  • 6.3 Dermal Toxicity
  • 6.4 Carcinogenicity
  • 6.5 Ocular Toxicity
  • 6.6 Genotoxicity
  • 6.7 Neurotoxicity
  • 6.8 Organ-Specific Toxicity
  • 6.9 Other Test Types

7 Global Toxicology Drug Screening Market, By Technology

  • 7.1 Introduction
  • 7.2 High-Throughput Screening
  • 7.3 Genomics
  • 7.4 Transcriptomics
  • 7.5 Toxicogenomics
  • 7.6 Molecular Screening
  • 7.7 Other Technologies

8 Global Toxicology Drug Screening Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals and Trauma Centers
  • 8.3 Forensic Laboratories
  • 8.4 Diagnostic Laboratories
  • 8.5 Rehabilitation Centers
  • 8.6 Pharmaceutical & Biotechnology Companies
  • 8.7 Other End Users

9 Global Toxicology Drug Screening Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Covance, Inc.
  • 11.2 Agilent Technologies Inc.
  • 11.3 Enzo Life Sciences Inc.
  • 11.4 Danaher
  • 11.5 Alere, Inc.
  • 11.6 BioReliance, Inc.
  • 11.7 Eurofins Scientific
  • 11.8 Bio-Rad Laboratories Inc.
  • 11.9 Promega Corporation
  • 11.10 GE Healthcare
  • 11.11 Thermo Fisher Scientific Inc.
  • 11.12 Charles River Laboratories International Inc.

List of Tables

  • Table 1 Global Toxicology Drug Screening Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Toxicology Drug Screening Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Toxicology Drug Screening Market Outlook, By Cardiovascular Disease Drug Screening (2021-2030) ($MN)
  • Table 4 Global Toxicology Drug Screening Market Outlook, By Obesity Drug Screening (2021-2030) ($MN)
  • Table 5 Global Toxicology Drug Screening Market Outlook, By Diabetes Drug Screening (2021-2030) ($MN)
  • Table 6 Global Toxicology Drug Screening Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Toxicology Drug Screening Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 8 Global Toxicology Drug Screening Market Outlook, By Acute Systemic Toxicity (2021-2030) ($MN)
  • Table 9 Global Toxicology Drug Screening Market Outlook, By Dermal Toxicity (2021-2030) ($MN)
  • Table 10 Global Toxicology Drug Screening Market Outlook, By Carcinogenicity (2021-2030) ($MN)
  • Table 11 Global Toxicology Drug Screening Market Outlook, By Ocular Toxicity (2021-2030) ($MN)
  • Table 12 Global Toxicology Drug Screening Market Outlook, By Genotoxicity (2021-2030) ($MN)
  • Table 13 Global Toxicology Drug Screening Market Outlook, By Neurotoxicity (2021-2030) ($MN)
  • Table 14 Global Toxicology Drug Screening Market Outlook, By Organ-Specific Toxicity (2021-2030) ($MN)
  • Table 15 Global Toxicology Drug Screening Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 16 Global Toxicology Drug Screening Market Outlook, By Technology (2021-2030) ($MN)
  • Table 17 Global Toxicology Drug Screening Market Outlook, By High-Throughput Screening (2021-2030) ($MN)
  • Table 18 Global Toxicology Drug Screening Market Outlook, By Genomics (2021-2030) ($MN)
  • Table 19 Global Toxicology Drug Screening Market Outlook, By Transcriptomics (2021-2030) ($MN)
  • Table 20 Global Toxicology Drug Screening Market Outlook, By Toxicogenomics (2021-2030) ($MN)
  • Table 21 Global Toxicology Drug Screening Market Outlook, By Molecular Screening (2021-2030) ($MN)
  • Table 22 Global Toxicology Drug Screening Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 23 Global Toxicology Drug Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 24 Global Toxicology Drug Screening Market Outlook, By Hospitals and Trauma Centers (2021-2030) ($MN)
  • Table 25 Global Toxicology Drug Screening Market Outlook, By Forensic Laboratories (2021-2030) ($MN)
  • Table 26 Global Toxicology Drug Screening Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 27 Global Toxicology Drug Screening Market Outlook, By Rehabilitation Centers (2021-2030) ($MN)
  • Table 28 Global Toxicology Drug Screening Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 29 Global Toxicology Drug Screening Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.